Patient Identification

Is ZYNTEGLO indicated for your patient?

ZYNTEGLO is a one-time gene therapy that expands options for patients with transfusion-dependent β-thalassaemia (TDT)
≥12 years of age who do not have a β0/β0 genotype and who do not have an HLA-matched related donor.1 

CONSIDER TREATMENT FOR PATIENTS WHO MEET THESE CRITERIA1:

  • Diagnosed with TDT
  • Who do not have a β0/β0 genotype
  • Patients ≥12 years of age
  • Appropriate for haematopoietic stem cell transplant (HSCT)
  • No human leukocyte antigen (HLA)–matched related haematopoietic stem cell donor available
CONTRAINDICATIONS1
  • Hypersensitivity to the active substance or to any of the excipients
  • Pregnancy and breastfeeding
  • Previous treatment with HSC gene therapy
  • Contraindications to the mobilisation agents and the myeloablative conditioning agent must be considered
Please consult the full Summary of Product Characteristics (SmPC) and the Prescribing Information (PI) before prescribing.
*Patients were considered to be transfusion-dependent if they had a history of transfusions of at least 100 mL/kg/year of RBCs or received ≥ 8 transfusions of RBCs per year in the 2 years preceding enrolment
How does ZYNTEGLO work?